Alliance Pharma FY profits seen in line with expectations
By Iain Gilbert
Date: Friday 31 Jan 2025
(Sharecast News) - International healthcare firm Alliance Pharma said on Friday that FY24 group profits would be in line with expectations despite a modest downturn in revenues.
Alliance Pharma said it had delivered group see-through revenues of £180.3m in FY24, down 1% year-on-year, but noted that while revenues declined in some of its brands, it had delivered a "strong performance" in Kelo-Cote, MacuShield, Hydromol and Forceval.
Chief executive Nick Sedgwick said: " I am pleased that performance in 2024 is in-line with expectations. Whilst we have much to do as we work on our transformation plans, I am confident that our strong portfolio of clinically differentiated brands will deliver predictable organic revenue growth over the mid-long term."
As of 0930 GMT, Alliance Pharma shares were up 0.33% at 61.40p.
Reporting by Iain Gilbert at Sharecast.com
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN